Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state:Also provided are processes of manufacture and methods of using the crystalline forms.製備抗HCV化合物5-(3,3-二甲基丁炔-1-基)-3-[(順-4-羥-4-{[(3S)-四氫呋喃-3-基氧基]甲基}環己基){[(1R)-4-甲基環己-3-烯-1-基]羰基}胺基]噻吩-2-甲酸(化合物I)之晶形和非晶形固體形式,且以固態作特徵分析:亦提供晶形形式之製造方法及使用方法。
